PMC:7264098 / 23180-23321
Annnotations
LitCovid-PMC-OGER-BB
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T332 | 66-76 | SP_7 | denotes | SARS-CoV-2 |
T333 | 96-100 | DG_47 | denotes | MSCs |
T66586 | 66-76 | SP_7 | denotes | SARS-CoV-2 |
T50773 | 96-100 | DG_47 | denotes | MSCs |
LitCovid-PubTator
Id | Subject | Object | Predicate | Lexical cue | tao:has_database_id |
---|---|---|---|---|---|
456 | 66-87 | Disease | denotes | SARS-CoV-2 infections | MESH:C000657245 |
LitCovid-PD-MONDO
Id | Subject | Object | Predicate | Lexical cue | mondo_id |
---|---|---|---|---|---|
T141 | 66-74 | Disease | denotes | SARS-CoV | http://purl.obolibrary.org/obo/MONDO_0005091 |
T142 | 66-70 | Disease | denotes | SARS | http://purl.obolibrary.org/obo/MONDO_0005091 |
T143 | 77-87 | Disease | denotes | infections | http://purl.obolibrary.org/obo/MONDO_0005550 |
LitCovid-sentences
Id | Subject | Object | Predicate | Lexical cue |
---|---|---|---|---|
T136 | 0-141 | Sentence | denotes | In the majority of clinical trials investigating the treatment of SARS-CoV-2 infections so far, MSCs are delivered via the intravenous route. |